| Autor: |
Costiniuk, Cecilia T., Lee, Terry, Singer, Joel, Galipeau, Yannick, Arnold, Corey, Langlois, Marc-André, Needham, Judy, Jenabian, Mohammad-Ali, Burchell, Ann N., Samji, Hasina, Chambers, Catharine, Walmsley, Sharon, Ostrowski, Mario, Kovacs, Colin, Tan, Darrell H. S., Harris, Marianne, Hull, Mark, Brumme, Zabrina L., Lapointe, Hope R., Brockman, Mark A. |
| Předmět: |
|
| Zdroj: |
Vaccines; May2024, Vol. 12 Issue 5, p447, 18p |
| Abstrakt: |
COVID-19 breakthrough infection (BTI) can occur despite vaccination. Using a multi-centre, prospective, observational Canadian cohort of people with HIV (PWH) receiving ≥2 COVID-19 vaccines, we compared the SARS-CoV-2 spike (S) and receptor-binding domain (RBD)-specific IgG levels 3 and 6 months post second dose, as well as 1 month post third dose, in PWH with and without BTI. BTI was defined as positivity based on self-report measures (data up to last study visit) or IgG data (up to 1 month post dose 3). The self-report measures were based on their symptoms and either a positive PCR or rapid antigen test. The analysis was restricted to persons without previous COVID-19 infection. Persons without BTI remained COVID-19-naïve until ≥3 months following the third dose. Of 289 participants, 92 developed BTI (31.5 infections per 100 person-years). The median days between last vaccination and BTI was 128 (IQR 67, 176), with the most cases occurring between the third and fourth dose (n = 59), corresponding to the Omicron wave. In analyses adjusted for age, sex, race, multimorbidity, hypertension, chronic kidney disease, diabetes and obesity, a lower IgG S/RBD (log10 BAU/mL) at 1 month post dose 3 was significantly associated with BTI, suggesting that a lower IgG level at this time point may predict BTI in this cohort of PWH. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
